Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05703672 · ClinicalTrials.gov registry record · Phase 3
Switching to E-cigarettes in Smokers Not Interested in Quitting
A Phase 3 study of Smoking Reduction, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 2
- Study locations
NCT05703672: Recruiting Phase 3 study of Smoking Reduction, sponsored by University of Kansas Medical Center.
NCT05703672 is a Phase 3 study of Smoking Reduction that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 500 participants, above the 238-participant average among 10 other Smoking Reduction trials with a reported enrollment target (110% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05703672, a Phase 3 study of Smoking Reduction, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objectives of this application are to 1) compare short- and long-term harm reduction and abuse liability potential of a nicotine salt pod-based electronic cigarettes (EC) in adult (AA) exclusive EC, dual cig-EC, and exclusive cig users, 2) characterize factors that predict who switches fully, partially, or not at all, and 3) examine if harm reduction can be further enhanced by treating dual users with varenicline (VAR) to eliminate cigarette smoking.
Primary Outcome
Reduction in toxicant exposure as measured by NNAL excretion from baseline to week 6.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Varenicline Tartrate
- OTHER Electronic cigarette
Study Locations (2)
Missouri
- Swope Health Central - Kansas City
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-07-17 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 3 |
What NCT05703672 shows while recruiting
NCT05703672 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 238-participant average among 10 other Smoking Reduction trials with a reported enrollment target (110% higher).
The record links to 1 condition, with Smoking Reduction appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05703672 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05703672 about?
NCT05703672 is a clinical study titled "Switching to E-cigarettes in Smokers Not Interested in Quitting". The objectives of this application are to 1) compare short- and long-term harm reduction and abuse liability potential of a nicotine salt pod-based electronic cigarettes (EC) in adult (AA) exclusive EC, dual cig-EC, and exclusive cig users, 2) characterize factors that predict who switches fully, pa...
What is the current status of trial NCT05703672?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2023-07-17. Estimated completion is 2027-02-28.
What conditions does trial NCT05703672 study?
This clinical trial studies the following conditions: Smoking Reduction.
What interventions are being tested in trial NCT05703672?
The interventions under investigation include: Placebo (DRUG), Varenicline Tartrate (DRUG), Electronic cigarette (OTHER).
Who is sponsoring clinical trial NCT05703672?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05703672 being conducted?
This trial has 2 study locations across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Reduction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05703672's enrollment target sits among peer trials
500 3rd of 10 higher than 8 of 10 other Smoking Reduction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Reduction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
RECRUITING · Phase 4
-
The Impact of Menthol Flavoring on Switching in Adult Menthol Smokers
RECRUITING · NA
-
Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia
RECRUITING · NA
-
Trauma-Informed Care for Smoking Cessation for Pregnancy
RECRUITING · NA
-
A Study Evaluating the Use of an Indoor Air Quality Monitor to Promote a Smoke-free Home
RECRUITING · NA
-
rTMS-concurrent Behavioral Priming for Reducing Smoking Cravings
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI